These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 26215780)

  • 1. Use of colistin-containing products within the European Union and European Economic Area (EU/EEA): development of resistance in animals and possible impact on human and animal health.
    Catry B; Cavaleri M; Baptiste K; Grave K; Grein K; Holm A; Jukes H; Liebana E; Lopez Navas A; Mackay D; Magiorakos AP; Moreno Romo MA; Moulin G; Muñoz Madero C; Matias Ferreira Pomba MC; Powell M; Pyörälä S; Rantala M; Ružauskas M; Sanders P; Teale C; Threlfall EJ; Törneke K; van Duijkeren E; Torren Edo J
    Int J Antimicrob Agents; 2015 Sep; 46(3):297-306. PubMed ID: 26215780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin.
    Giske CG
    Clin Microbiol Infect; 2015 Oct; 21(10):899-905. PubMed ID: 26027916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Colistin use in ventilator-associated pneumonia due to panresistant Pseudomonas aeruginosa and Acinetobacter baumannii].
    Taşbakan MS; Pullukçu H; Ekren PK; Oz AT; Midilli M; Aydemir S; Gürgün A; Başoğlu OK; Bacakoğlu F
    Mikrobiyol Bul; 2009 Jan; 43(1):61-70. PubMed ID: 19334381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to colistin: what is the fate for this antibiotic in pig production?
    Rhouma M; Beaudry F; Letellier A
    Int J Antimicrob Agents; 2016 Aug; 48(2):119-26. PubMed ID: 27234675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies.
    Petrosillo N; Ioannidou E; Falagas ME
    Clin Microbiol Infect; 2008 Sep; 14(9):816-27. PubMed ID: 18844682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.
    Koomanachai P; Tiengrim S; Kiratisin P; Thamlikitkul V
    Int J Infect Dis; 2007 Sep; 11(5):402-6. PubMed ID: 17291803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
    Kwa AL; Loh C; Low JG; Kurup A; Tam VH
    Clin Infect Dis; 2005 Sep; 41(5):754-7. PubMed ID: 16080101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Etest method for detecting colistin susceptibility of multidrug-resistant Gram-negative isolates in Vietnam.
    Nhung PH; Miyoshi-Akiyama T; Phuong DM; Shimada K; Anh NQ; Binh NG; Thanh do V; Ohmagari N; Kirikae T
    J Infect Chemother; 2015 Aug; 21(8):617-9. PubMed ID: 25960156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
    Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K
    Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational use of intravenous polymyxin B and colistin: A review.
    Zakuan ZD; Suresh K
    Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study.
    Matthaiou DK; Michalopoulos A; Rafailidis PI; Karageorgopoulos DE; Papaioannou V; Ntani G; Samonis G; Falagas ME
    Crit Care Med; 2008 Mar; 36(3):807-11. PubMed ID: 18431267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections.
    Huang J; Tang YQ; Sun JY
    Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.
    Li J; Nation RL; Turnidge JD; Milne RW; Coulthard K; Rayner CR; Paterson DL
    Lancet Infect Dis; 2006 Sep; 6(9):589-601. PubMed ID: 16931410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options.
    Kempf M; Rolain JM
    Int J Antimicrob Agents; 2012 Feb; 39(2):105-14. PubMed ID: 22113193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections.
    Lesho E; Yoon EJ; McGann P; Snesrud E; Kwak Y; Milillo M; Onmus-Leone F; Preston L; St Clair K; Nikolich M; Viscount H; Wortmann G; Zapor M; Grillot-Courvalin C; Courvalin P; Clifford R; Waterman PE
    J Infect Dis; 2013 Oct; 208(7):1142-51. PubMed ID: 23812239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colistin: re-emergence of the 'forgotten' antimicrobial agent.
    Dhariwal AK; Tullu MS
    J Postgrad Med; 2013; 59(3):208-15. PubMed ID: 24029199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colistin use and colistin resistance in bacteria from animals.
    Kempf I; Jouy E; Chauvin C
    Int J Antimicrob Agents; 2016 Dec; 48(6):598-606. PubMed ID: 27836380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009].
    Hamouche E; Sarkis DK
    Pathol Biol (Paris); 2012 Jun; 60(3):e15-20. PubMed ID: 21719212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients.
    Falagas ME; Rafailidis PI; Matthaiou DK; Virtzili S; Nikita D; Michalopoulos A
    Int J Antimicrob Agents; 2008 Nov; 32(5):450-4. PubMed ID: 18768302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.